Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
A recent randomized study comparing structured lifestyle modification (a cornerstone in the currently recommended treatment of NASH) to liraglutide 3 mg/day without lifestyle modifications showed similar reductions in ALT and liver stiffness with no difference in bodyweight variations
It does this by stimulating neurons in the central nervous system in a way that releases two neurotransmitters related to appetite: dopamine and norepinephrine
Strong adoption of advanced GLP-1 therapies by healthcare providers, coupled with growing clinical evidence supporting cardiovascular and weight-loss benefits, is driving market demand
Many of these are also risk factors for fatty liver disease (more on that below)
What to monitor: This is the dose where nutritional adequacy becomes critical
US$ 25.13
US$ 27.33
US$ 21.71
